Female participants of childbearing potential must agree to use an adequate method of contraception during the study treatment period and for at least  days after the last dose of study treatment.
If female of child-bearing potential, is willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug.
Participants of reproductive potential must be willing to use adequate contraception for the course of the study through  days after the last dose of pembrolizumab or through  days after the last dose of paclitaxel, docetaxel or irinotecan
Subject is willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug (male and female participants of childbearing potential)
Female participants of childbearing potential must be willing to use adequate contraception for the course of the study through  days after the last dose of study medication
Male participants with partners of must childbearing potential must be willing to use adequate contraception for the course of the study through  days after the last dose of study medication
If female of childbearing potential, is willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug.
Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study medication
Female participants of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through  days after the last dose of study treatment.
Female patients of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through  days after the last dose of study medication
Be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study medication (male and female subjects of childbearing potential
Female participants of childbearing age must be willing to use contraception methods, or abstain from sexual activity throughout the course of the study and for  months after the last dose of atezolizumab
Female subjects of childbearing potential must be willing to use  methods of contraception, or abstain from heterosexual sexual intercourse for two weeks before the time of the first dose of study medication, while on study, through  days after the last dose of study medication
Female participants of childbearing potential must be willing to use adequate contraception for the course of the study starting with the first dose of study medication through  days after the last dose of SOC therapy or  days after the last pembrolizumab dose
Is willing to use an adequate method of contraception for the course of the study through at least  days or longer based on local regulation after the last dose of study drug (male and female participants of childbearing potential).
Female participants of childbearing potential must agree to use adequate contraception  days prior to study start, continuing throughout the study, and for up to  days after the last dose of lenalidomide (or  days after the last dose of pembrolizumab).
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug.
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of pembrolizumab or  days after chemotherapy treatment.
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug.
If female of childbearing potential, is willing to use adequate contraception for the course of the study through  days after the last dose of study medication or through  days after last dose of chemotherapeutic agents.
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug.
Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through  days after the last dose of study drug
Is willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug (male and female participants of childbearing potential)
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study drug
Female participants of childbearing potential must be willing to use adequate contraception during the course of the study through  days after the last dose of study drug
Female participants of childbearing potential must be willing to use adequate contraception for the course of the study through  days after the last dose of study medication
Male participants with a female partner(s) of childbearing potential must be willing to use  adequate methods of contraception from screening through  days after the last dose of pembrolizumab
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study medication
Female participants of childbearing potential must have a negative urine or serum pregnancy test within  hours prior to randomization and be willing to use an adequate method of contraception (e.g. abstinence, intrauterine device, diaphragm with spermicide, etc.) for the course of the study through  days after the last dose of study treatment and up to  days after last dose of cisplatin
Males and female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  months after the last dose of study treatment for participants who have received cyclophosphamide, and  months after the last dose of study treatment for participants who did not.
Female and male participants of reproductive potential must agree to use adequate contraception during the course of the study through  days after study the last dose of study therapy
Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study medication
Subjects of childbearing potential not willing to use adequate contraception during study and  months after last dose of crenolanib
Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through  days after the last dose of chemotherapy.
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of chemotherapy or through  days after the last dose of pembrolizumab, whichever is greater.
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days (or longer as specified by local institutional guidelines) after the last dose of study drug.
Men with partners of childbearing potential willing to use adequate contraceptive measures during the study and for  days after the last dose of study medication.
Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days (for participants receiving pembrolizumab) or  days (for participants receiving BV) after the last dose of study drug.
Male participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through  days (for participants receiving pembrolizumab) or  days (for participants receiving BV) after the last dose of study drug.